BRPI0415639A - formas de dosagem de oxicodona de liberação controlada, oral, uma vez por dia - Google Patents

formas de dosagem de oxicodona de liberação controlada, oral, uma vez por dia

Info

Publication number
BRPI0415639A
BRPI0415639A BRPI0415639-0A BRPI0415639A BRPI0415639A BR PI0415639 A BRPI0415639 A BR PI0415639A BR PI0415639 A BRPI0415639 A BR PI0415639A BR PI0415639 A BRPI0415639 A BR PI0415639A
Authority
BR
Brazil
Prior art keywords
profiles
dosage forms
controlled release
oral dosage
once daily
Prior art date
Application number
BRPI0415639-0A
Other languages
English (en)
Inventor
Stephen Hwang
Padmaja Shivanand
Nisht B Modi
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of BRPI0415639A publication Critical patent/BRPI0415639A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

"FORMAS DE DOSAGEM DE OXICODONA DE LIBERAçãO CONTROLADA, ORAL, UMA VEZ POR DIA". Formulações de oxicodona são fornecidas as quais produzem perfis de plasma em estado constante em vivo substancialmente fixos. Níveis de tolerância associados com tais perfis e níveis de tolerância associados com perfis bifásicos não são mostrados serem estatisticamente diferentes. Os perfis de plasma em estado constante em vivo substancialmente fixos são produzidos por formas de dosagem que têm perfis de liberação de ordem substancialmente zero. Tais perfis de liberação produzem níveis de C~ max~ em vivo de dose única baixa que podem reduzir a probabilidade de efeitos colaterais adversos.
BRPI0415639-0A 2003-10-29 2004-10-28 formas de dosagem de oxicodona de liberação controlada, oral, uma vez por dia BRPI0415639A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51588003P 2003-10-29 2003-10-29
PCT/US2004/036132 WO2005041968A2 (en) 2003-10-29 2004-10-28 Once-a-day, oral, controlled-release, oxycodone dosage forms

Publications (1)

Publication Number Publication Date
BRPI0415639A true BRPI0415639A (pt) 2006-12-12

Family

ID=34549453

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415639-0A BRPI0415639A (pt) 2003-10-29 2004-10-28 formas de dosagem de oxicodona de liberação controlada, oral, uma vez por dia

Country Status (14)

Country Link
EP (1) EP1677798A2 (pt)
JP (1) JP2007509979A (pt)
KR (1) KR20060108690A (pt)
CN (1) CN1933837A (pt)
AU (1) AU2004285547A1 (pt)
BR (1) BRPI0415639A (pt)
CA (1) CA2546691A1 (pt)
EC (1) ECSP066534A (pt)
IL (1) IL175193A0 (pt)
MA (1) MA28215A1 (pt)
NO (1) NO20062398L (pt)
RU (1) RU2006118323A (pt)
WO (1) WO2005041968A2 (pt)
ZA (1) ZA200604310B (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100889069B1 (ko) 1999-10-29 2009-03-17 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
AU2738302A (en) 2000-10-30 2002-05-15 Euro Celtique Sa Controlled release hydrocodone formulations
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
CA2713128C (en) 2008-01-25 2016-04-05 Gruenenthal Gmbh Pharmaceutical dosage form
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
AU2009243681B2 (en) 2008-05-09 2013-12-19 Grunenthal Gmbh Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
CN102639118B (zh) 2009-07-22 2015-07-29 格吕伦塔尔有限公司 氧化稳定的抗干扰剂型
KR101738369B1 (ko) 2009-07-22 2017-05-22 그뤼넨탈 게엠베하 핫 멜트 압출된 제어 방출 투여형
US20110150989A1 (en) * 2009-12-22 2011-06-23 Mallinkckrodt Inc. Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
WO2011124953A2 (en) * 2010-04-07 2011-10-13 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
BR112013005194A2 (pt) 2010-09-02 2016-05-03 Gruenenthal Gmbh forma de dosagem resistente à violação compreendendo sal inorgânico
TWI516286B (zh) 2010-09-02 2016-01-11 歌林達股份有限公司 含陰離子聚合物之抗破碎劑型
EA201400172A1 (ru) 2011-07-29 2014-06-30 Грюненталь Гмбх Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
BR112014001091A2 (pt) 2011-07-29 2017-02-14 Gruenenthal Gmbh comprimido resistente à adulteração que fornece liberação imediata do fármaco
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
EP2838512B1 (en) 2012-04-18 2018-08-22 Grünenthal GmbH Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
EP3003279A1 (en) 2013-05-29 2016-04-13 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
BR112016000194A8 (pt) 2013-07-12 2019-12-31 Gruenenthal Gmbh forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila
EP3073994A1 (en) 2013-11-26 2016-10-05 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
WO2015173195A1 (en) 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
EA201692388A1 (ru) 2014-05-26 2017-05-31 Грюненталь Гмбх Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
WO2016170097A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
JP2018526414A (ja) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
BR112019002007B1 (pt) 2016-08-10 2024-01-16 F. Hoffmann-La Roche Ag Composição farmacêutica e uso de uma composição farmacêutica

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914131A (en) * 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
WO2003092648A1 (en) * 2002-04-29 2003-11-13 Alza Corporation Methods and dosage forms for controlled delivery of oxycodone
CA2487786A1 (en) * 2002-05-31 2003-12-11 Alza Corporation Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone

Also Published As

Publication number Publication date
ECSP066534A (es) 2006-11-24
CN1933837A (zh) 2007-03-21
AU2004285547A1 (en) 2005-05-12
EP1677798A2 (en) 2006-07-12
ZA200604310B (en) 2007-11-28
WO2005041968A3 (en) 2006-06-22
IL175193A0 (en) 2008-04-13
JP2007509979A (ja) 2007-04-19
MA28215A1 (fr) 2006-10-02
WO2005041968A2 (en) 2005-05-12
KR20060108690A (ko) 2006-10-18
CA2546691A1 (en) 2005-05-12
RU2006118323A (ru) 2007-12-10
NO20062398L (no) 2006-07-27

Similar Documents

Publication Publication Date Title
BRPI0415639A (pt) formas de dosagem de oxicodona de liberação controlada, oral, uma vez por dia
EP1670450B8 (en) Pharmaceutical compositions and method of using levodopa and carbidopa
TW200505881A (en) Tri(cyclo) substituted amide compounds
WO2005041924A3 (en) Administration of levodopa and carbidopa
GEP20125701B (en) Application of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile
WO2010009892A8 (en) Compositions for the treatment of pain and/or inflamation
TW200716628A (en) Novel compounds
GEP20247585B (en) Furoindazole derivatives
EA200401227A1 (ru) Система доставки лекарства с контролируемым высвобождением, включающая правастатин
MY135829A (en) Analeptic and drug combinations
EA200702522A1 (ru) Система доставки лекарств в полость рта и способы ее применения
PL1638582T3 (pl) Zastosowanie kwasu hialuronowego do wytwarzania środków do leczenia nawracających aft w jamie ustnej
IS7492A (is) Lyfjablöndu uppskriftir, sem innifela melantónín
CY1118967T1 (el) Φαρμακευτικες συνθεσεις υψηλης δοσης βιοτινης
ZA201000581B (en) 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives,preparation and therapeutic use thereof
IL182681A0 (en) Coadministration of tigecycline and digoxin
ATE410152T1 (de) Therapeutisches system mit amoxicillin und clavulansäure
CL2008002223A1 (es) Compuestos derivados de 9-desoxo-9a-metil-9a-aza-9a-homoeritromicina a 2'-o-sustituida; proceso de preparación; compuesto intermediario; composición farmacéutica; y su uso en el tratamiento y/o profilaxis de la malaria.
HRP20090513T1 (hr) S-mirtazapin, namijenjen liječenju napadaja vrućine
EA200501565A1 (ru) Предназначенная для перорального приёма лекарственная форма для антагонистов протонного насоса
MY140194A (en) Novel fusidic acid derivatives
TW200626140A (en) Preventing vertical endoparasite infections
NO20065791L (no) Asyklovir-formuleringer
SE0203817D0 (sv) New composition
BRPI0415428A (pt) formulações terapêuticas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.